Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor

Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye

SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A

Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch

Article first published online: January 27, 2019

Coates S, Pohl O, Gotteland JP, Täubel J, Lorch U. Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Ther Innov Regul Sci. 2020;54(1):184‐194. doi:10.1007/s43441-019-00044-y

A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer

Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2018, 6-10 October 2018, Denver, CO

Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101

Effects of the oral oxytocin receptor antagonist nolasiban on early embryonic development

O. Pohl, D. Perks, R. Sisti, J.P. Gotteland

ESHRE Annual Conference, 01-04 July 2018, Barcelona, Spain
Abstract P-121 on Pages i196-i197

Abstract P-121 on Pages i196-i197 – Human Reproduction, Volume 33, Issue suppl_1, July 2018, Pages i1–i541,

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor

Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

Journal of Pharmacology and Experimental Therapeutics August 2018, 366 (2) 349-364; doi:10.1124/jpet.118.247668

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. Br J Clin Pharmacol. 2018;84(8):1839‐1855. doi:10.1111/bcp.13622

ObsEva on page 17 of Understanding Fertility Special Report 2018

Special report in the Raconteur Article in ‘The Times’ Click here for publication link IVF ‘BREAKTHROUGH’ TREATMENT Pioneering use of…

Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits

Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037

Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women

Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl

Täubel, J., Lorch, U., Coates, S., Fernandes, S., Foley, P., Ferber, G., Gotteland, J.‐P. and Pohl, O. (2018), Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical Pharmacology in Drug Development, 7: 889-900. doi:10.1002/cpdd.447